Key points are not available for this paper at this time.
Daily injections of anakinra markedly improved clinical and laboratory manifestations in patients with neonatal-onset multisystem inflammatory disease, with or without CIAS1 mutations. (ClinicalTrials.gov number, NCT00069329 ClinicalTrials.gov.).
Goldbach‐Mansky et al. (Wed,) studied this question.